Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine

Vaccine

Volumn 28, Issue 33, 2010, Pages 5407-5413

  Dauner, Joseph G ^a   Pan, Yuanji ^a   Hildesheim, Allan ^b   Harro, Clayton ^c   Pinto, Ligia A ^a  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

HPV; Humoral response; Vaccination; VLP

Indexed keywords

HUMAN PAPILLOMAVIRUS 16 L1 VIRUS LIKE PARTICLE VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; NOVAVAX; PLACEBO; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNITY; MEMORY CELL; NONHUMAN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNOLOGIC MEMORY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

EID: 77955055957     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.018     Document Type: Article

References (40)

1. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370(9590 (September 8)):890-907.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1 (September)):12-19.
3. Rambout L., Hopkins L., Hutton B., Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007, 177(5 (August 28)):469-479.
4. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002, 347(21 (November 21)):1645-1651.
5. Kirnbauer R., Booy F., Cheng N., Lowy D.R., Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992, 89(24 (December 15)):12180-12184.
6. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 1993, 67(12 (December)):6929-6936.
7. Harro C.D., Pang Y.Y., Roden R.B., Hildesheim A., Wang Z., Reynolds M.J., et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001, 93(4 (February 21)):284-292.
8. Schwarz T.F., Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008, 110(September (3 Suppl. 1)):S1-10.
9. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69(6 (June)):3959-3963.
10. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92(25 (December 5)):11553-11557.
11. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364(9447 (November 13-19)):1757-1765.
12. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26(29-30 (July 4)):3608-3616.
13. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4(6 (November-December)):425-434.
14. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix() and Gardasil((R)) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5(10 (October)):705-719.
15. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24(33-34 (August 14)):5937-5949.
16. Bernasconi N.L., Traggiai E., Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298(5601 (December 13)):2199-2202.
17. Wrammert J., Smith K., Miller J., Langley W.A., Kokko K., Larsen C., et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 2008, 453(7195 (May 29)):667-671.
18. Crotty S., Aubert R.D., Glidewell J., Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004, 286(1-2 (March)):111-122.
19. Pinto L.A., Edwards J., Castle P.E., Harro C.D., Lowy D.R., Schiller J.T., et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003, 188(2 (July 15)):327-338.
20. Polanec J., Seppala I., Rousseau S., Hedman K. Evaluation of protein-denaturing immunoassays for avidity of immunoglobulin G to rubella virus. J Clin Lab Anal 1994, 8(1):16-21.
21. Roden R.B., Armstrong A., Haderer P., Christensen N.D., Hubbert N.L., Lowy D.R., et al. Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 1997, 71(8 (August)):6247-6252.
22. Christensen N.D., Dillner J., Eklund C., Carter J.J., Wipf G.C., Reed C.A., et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 1996, 223(1 (September 1)):174-184.
23. Blanchard Rohner G., Snape M.D., Kelly D.F., John T., Morant A., Yu L.M., et al. The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. J Immunol 2008, 180(4 (February 15)):2165-2173.
24. Crotty S., Felgner P., Davies H., Glidewell J., Villarreal L., Ahmed R. Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 2003, 171(10 (November 15)):4969-4973.
25. Jayasekera C.R., Harris J.B., Bhuiyan S., Chowdhury F., Khan A.I., Faruque A.S., et al. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J Infect Dis 2008, 198(7 (October 1)):1055-1061.
26. Quinn C.P., Dull P.M., Semenova V., Li H., Crotty S., Taylor T.H., et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004, 190(7 (October 1)):1228-1236.
27. Sasaki S., He X.S., Holmes T.H., Dekker C.L., Kemble G.W., Arvin A.M., et al. Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One 2008, 3(8):e2975.
28. Shokrgozar M.A., Sam M.R., Amirkhani A., Shokri F. Frequency analysis of HBsAg-specific B lymphocytes in high-responder individuals to recombinant hepatitis B vaccine: comparison of LDA and ELISPOT assays. Scand J Immunol 2006, 64(5 (November)):536-543.
29. Slifka M.K., Antia R., Whitmire J.K., Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998, 8(3 (March)):363-372.
30. Denoel P.A., Goldblatt D., de Vleeschauwer I., Jacquet J.M., Pichichero M.E., Poolman J.T. Quality of the Haemophilus influenzae type b (Hib) antibody response induced by diphtheria-tetanus-acellular pertussis/Hib combination vaccines. Clin Vaccine Immunol 2007, 14(10 (October)):1362-1369.
31. Longworth E., Borrow R., Goldblatt D., Balmer P., Dawson M., Andrews N., et al. Avidity maturation following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine in UK infants. Vaccine 2002, 20(19-20 (June 7)):2592-2596.
32. Nair N., Gans H., Lew-Yasukawa L., Long-Wagar A.C., Arvin A., Griffin D.E. Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis 2007, 196(9 (November 1)):1339-1345.
33. Poolman J., Kaufhold A., De Grave D., Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine 2001, 19(17-19 (March 21)):2280-2285.
34. Wuorimaa T., Dagan R., Vakevainen M., Bailleux F., Haikala R., Yaich M., et al. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J Infect Dis 2001, 184(9 (November 1)):1211-1215.
35. Hedman K., Seppala I. Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol 1988, 8(3 (May)):214-221.
36. Yasodhara P., Ramalakshmi B.A., Sarma M.K. A new approach to differentiate recent vs chronic toxoplasma infection: avidity elisa in toxoplasma serology. Indian J Med Microbiol 2001, 19(3 (July-September)):145-148.
37. McCloskey N., Turner M.W., Goldblatt T.D. Correlation between the avidity of mouse-human chimeric IgG subclass monoclonal antibodies measured by solid-phase elution ELISA and biospecific interaction analysis (BIA). J Immunol Methods 1997, 205(1 (June 23)):67-72.
38. Pichichero M.E., Voloshen T., Zajac D., Passador S. Avidity maturation of antibody to Haemophilus influenzae type b (Hib) after immunization with diphtheria-tetanus-acellular pertussis-hib-hepatitis B combined vaccine in infants. J Infect Dis 1999, 180(4 (October)):1390-1393.
39. Vauloup-Fellous C., Grangeot-Keros L. Humoral immune response after primary rubella virus infection and after vaccination. Clin Vaccine Immunol 2007, 14(5 (May)):644-647.
40. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 2006, 80(19 (October)):9577-9585.